Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 22K | 0 | 2M | 3M | 2M |
| Gross Profit | -4M | 0 | 2M | 3M | 2M |
| Operating Income | -64M | -61M | -93M | -62M | -40M |
| EBITDA | -60M | -55M | -61M | -58M | -37M |
| Net Income | -61M | -53M | -71M | -58M | -55M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.932
-2.00% today
1Y Change
-53.17%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Senti Biosciences, Inc. (SNTI) is a Healthcare stock with a market cap of $30.00M and listed on NASDAQ. The stock last traded around $0.93 and down 53.2% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +76.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +76.2%, free cash flow -5.4% with operating margin -289668.2% and ROIC -149.7%. Valuation already assumes a fairly strong business story at price/sales 1218.9. Stock Foundry combines SNTI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SNTI
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SNTI Max Drawdown
-67.70%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SNTI and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$2.3M
-30.3% YoY
FY Net Income
-$55.3M
+5.0% YoY
Free Cash Flow
-$40.2M
+47.3% YoY
Revenue Growth
+0.0%
EPS Growth
+76.2%
Gross Margin
-14777.3%
Net Margin
-279263.6%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 22K | 0 | 2M | 3M | 2M |
| Gross Profit | -4M | 0 | 2M | 3M | 2M |
| Operating Income | -64M | -61M | -93M | -62M | -40M |
| EBITDA | -60M | -55M | -61M | -58M | -37M |
| Net Income | -61M | -53M | -71M | -58M | -55M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 16M | 48M | 36M | 58M | 56M |
| Total Assets | 51M | 98M | 119M | 181M | 97M |
| Total Liabilities | 46M | 72M | 53M | 54M | 36M |
| Shareholder Equity | 6M | 26M | 67M | 127M | 60M |
| Total Debt | 29M | 34M | 38M | 37M | 23M |
| Net Debt | 12M | -15M | 2M | -21M | -33M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
35M
+0.7% YoY
Capital Expenditures
6M
+86.6% YoY
Free Cash Flow
40M
+47.3% YoY
Key ratios
Gross Margin
-14777.3%
Operating Margin
-289668.2%
Net Margin
-279263.6%
ROE
-322.4%
Debt / Equity
5.17x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.